Corbus Pharmaceuticals Holdings, Inc.
Pitch Summary: Corbus Pharmaceuticals is developing CRB-701, a next-generation ADC targeting Nectin-4 for advanced solid tumors, with a strategic shift away from competing in the metastatic urothelial carcinoma (mUC) space due to competition. The company is now focusing on unmet needs in 2nd-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer, where it […]
